Your browser doesn't support javascript.
loading
Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing.
Munoz-Zuluaga, Carlos A; Heymann, Jonas J; Solomon, James P; Patel, Ami; Siddiqui, Momin T; Scognamiglio, Theresa; Gokozan, Hamza N.
Afiliación
  • Munoz-Zuluaga CA; Divisions of Cytopathology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, US.
  • Heymann JJ; Divisions of Head and Neck Pathology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, US.
  • Solomon JP; Divisions of Cytopathology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, US.
  • Patel A; Divisions of Molecular and Genomic Pathology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, US.
  • Siddiqui MT; Divisions of Cytopathology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, US.
  • Scognamiglio T; Divisions of Cytopathology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, US.
  • Gokozan HN; Divisions of Head and Neck Pathology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, US.
Am J Clin Pathol ; 161(5): 463-468, 2024 May 02.
Article en En | MEDLINE | ID: mdl-38104250
ABSTRACT

OBJECTIVES:

Afirma has recently introduced its Xpression Atlas (XA) as an adjunct to its Genomic Sequencing Classifier (GSC) for risk stratification of cytologically indeterminate thyroid nodules. We evaluated the performance of Afirma XA and associated pathologic findings for Afirma GSC suspicious nodules.

METHODS:

Intradepartmental records of thyroid fine-needle aspirations (FNAs) from January 2021 to December 2022 were identified and reviewed for patient and nodule characteristics, FNA findings, molecular test results, and final surgical pathology, if available.

RESULTS:

Material for Afirma GSC testing was collected in 624 thyroid FNAs, and 148 (24%) were classified as cytologically indeterminate. Afirma GSC testing was successful in 132 (89%) of those cases, of which 35 (27%) were Afirma GSC suspicious. Afirma XA testing was positive in 11 cases (11/35 [31%]). Eight (73%) patients underwent surgery that revealed 7 patients with papillary thyroid carcinoma and 1 patient with noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) (risk of malignancy 100% [8/8]). Among the 24 patients with negative Afirma XA results, 19 (79%) underwent surgery, revealing 5 patients with malignancy and 3 patients with NIFTP (risk of malignancy 42% [8/19]). Overall, the risk of malignancy for Afirma GSC suspicious nodules was 59% (16/27).

CONCLUSIONS:

Afirma XA improved risk stratification of thyroid disease with a high risk of malignancy in Afirma GSC suspicious nodules. A negative Afirma XA result, however, should not be used as a rule-out test.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Nódulo Tiroideo Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Clin Pathol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Nódulo Tiroideo Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Clin Pathol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido